CoChat

Preoperative CTLA-4 Blockade: Tolerability and Immune Monitoring in the Setting of a Presurgical Clinical Trial

Open access

Published version of a preprint

The DOI matches its Crossref record; 31 of the 33 references it cites were found in a registry or an index.

Abstract

PURPOSE: Cytotoxic T lymphocyte associated antigen (CTLA-4) blockade is being explored in numerous clinical trials as an immune-based therapy for different malignancies. Our group conducted the first preoperative clinical trial with the anti-CTLA-4 antibody ipilimumab in 12 patients with localized urothelial carcinoma of the bladder. EXPERIMENTAL DESIGN: Six patients were treated with 3 mg/kg/dose of anti-CTLA-4 and six patients were treated with 10 mg/kg/dose of antibody. Primary end points of the study were safety and immune monitoring. RESULTS: Most drug-related adverse events consisted of grade 1/2 toxicities. All patients had measurable immunologic pharmacodynamic effects, consisting of an increased frequency of CD4+ICOShi T cells in tumor tissues and the systemic circulation. To determine if CD4+ICOShi T cells could be a correlative marker for clinical outcome after treatment with anti-CTLA-4, a cohort of metastatic melanoma patients was studied retrospectively for frequency of CD4+ICOShi T cells and survival. Data from this small cohort of patients indicated that an increased frequency of CD4+ICOShi T cells, sustained over a period of 12 weeks of therapy, correlates with increased likelihood of clinical benefit consisting of overall survival. CONCLUSIONS: Our trial shows that anti-CTLA-4 therapy has a tolerable safety profile in the presurgical setting and that a preoperative model can be used to obtain biological data on human immune responses, which can efficiently guide the monitoring of patients treated in the metastatic disease setting.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1158/1078-0432.ccr-10-0569

Cites

31 of 31 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 31 references

Cited by

See all 482

Metadata

Authors
Carthon, B. C., Wolchok, J. D., Yuan, J., Kamat, A., Ng Tang, D. S., Sun, J., Ku, G., Troncoso, P., Logothetis, C. J., Allison, J. P., & Sharma, P.
Affiliations
  • Memorial Sloan Kettering Cancer Center (US)
  • Authors' Affiliations: Departments of 1Genitourinary Medical Oncology, 2Urology, 3Pathology, and 4Immunology, The University of Texas M.D. Anderson Cancer Center, Houston, Texas; 5Department of Medicine, 6Ludwig Center for Cancer Immunotherapy, and 7Department of Immunology, Memorial Sloan-Kettering Cancer Center, New York, New York; and 8Howard Hughes Medical Institute, Chevy Chase, MD
Corresponding author
Sharma, Padmanee
Venue
Clinical Cancer Research
Published
2010-05-13
Volume
16
Issue
10
Pages
2861-2871
ISSN
  • 1078-0432 (ISSN-L)
  • 1557-3265
OpenAlex
W2118503880
Cited by
460
References
33
Citations by year
2026: 6 · 2025: 19 · 2024: 22 · 2023: 26 · 2022: 19 · 2021: 25 · 2020: 38 · 2019: 19 · 2018: 39 · 2017: 39 · 2016: 68 · 2015: 49 · 2014: 18 · 2013: 32 · 2012: 19
FWCI
11.53
Type
journal article
Language
en
Open access
Locations
  • Clinical Cancer Research (publishedVersion)
  • PubMed (publishedVersion)
  • Europe PMC (PubMed Central) (acceptedVersion)
  • PubMed Central (acceptedVersion)
Funders
  • Howard Hughes Medical Institute
  • National Cancer Institute (P50CA140388, T32CA009666)
Topics
  • Health Sciences › Medicine › Oncology › Cancer Immunotherapy and Biomarkers
  • Health Sciences › Medicine › Surgery › Bladder and Urothelial Cancer Treatments
  • Life Sciences › Immunology and Microbiology › Immunology › Immunotherapy and Immune Responses
Keywords
CTLA-4 blockade, ipilimumab, neoadjuvant immunotherapy, bladder urothelial carcinoma, immune checkpoint inhibitors, drug safety, metastatic melanoma, overall survival, immune monitoring
MeSH terms
Ipilimumab, Aged, Antibodies, Monoclonal, Antigens, Differentiation, T-Lymphocyte, Antineoplastic Agents, Urinary Bladder Neoplasms, Carcinoma, Transitional Cell, Cell Separation, Female, Flow Cytometry, Humans, Immunohistochemistry, Immunotherapy, Male, Melanoma, Middle Aged, Phenotype, Urogenital Surgical Procedures, Biomarkers, Tumor, CD4-Positive T-Lymphocytes, Antigens, CD, Immunophenotyping, T-Lymphocyte Subsets, Neoadjuvant Therapy, Forkhead Transcription Factors, Inducible T-Cell Co-Stimulator Protein, CTLA-4 Antigen

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Preoperative CTLA-4 Blockade: Tolerability and Immune Monitoring in the Setting of a Presurgical Clinical Trial. https://app.cochat.ai/papers/10.1158/1078-0432.ccr-10-0569
The paper
Carthon, B. C., Wolchok, J. D., Yuan, J., Kamat, A., Ng Tang, D. S., Sun, J., Ku, G., Troncoso, P., Logothetis, C. J., Allison, J. P., & Sharma, P. (2010). Preoperative CTLA-4 Blockade: Tolerability and Immune Monitoring in the Setting of a Presurgical Clinical Trial. Clinical Cancer Research. https://doi.org/10.1158/1078-0432.ccr-10-0569

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.